## 10/594835

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 28 SEP 2006

Applicants:

Craig A. Coburn et al.

Serial No.:

To Be Assigned

Case No.: 21538YP

US Nat'l Filing Date:

September 28, 2006

Int'l Appl'n No.

PCT/US2005/010538

Int'l Filing Date:

March 29, 2005

For:

METHODS FOR DETECTING SUBSTANCES WHICH BIND

TO THE AMYLOID PRECURSOR PROTEIN OR BETA AMYLOID FRAGMENTS, AND BINDING COMPOUNDS

Mail Stop PCT Commissioner for Patents P.O. BOX 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

**EXPRESS MAIL CERTIFICATE** 

DATE OF DEPOSIT EXPRESS MAIL NO.

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail "Post Office to Addressee" on the above date in an envelope addressed

Commissioner for Patents, P. O. Box 1450, Alexandria, Virginia 22313-1450

MAILED BY

DATE

APS Rec'd PCT/BTO signed SEP 2006

Case No.

**210/59483**5

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application. Accordingly, it is believed that no fee is due.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

John C. Todaro, Reg. No. 36,036

Attorney for Applicant

MERCK & CO., Inc. P.O. Box 2000 Rahway, New Jersey 07065-0907 (732) 594-0125

Date: September 28, 2006

Su	Substitute for form 1449A/PTO		COMPLETE IF KNOWN			
I	INFORMATION DISCLOSURE			Application Number	To Be Assigned 10/594835	
C	STATEMENT BY APPLICANT			Filing Date	September 28, 2006	
3				First Named Inventor	PSRec'd PET/PTO 28 SEP 201	
			,	Group Art Unit	To Be Assigned	
	(use as many sheets as necessary)			Examiner Name	To Be Assigned	
Sheet	1	of	2	Attorney Docket Number	21538YP	

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY		
	Α	5,091,533		Belanger et al.	02/25/1992		
	В	US 2003/0200555		Hazuda at al.	10/23/2003		
	С	US 2003/0215896		Li et al.	11/20/2003		
	D	US 2005/0164311		Inglese et al.	07/28/2005		
-							

			FOREIC	SN PATENT	T DOCUMENTS		
Examiner Initials*	Cite No.	Office	Foreign Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
	E		WO 02/094985		Merck & Co., Inc.	11/18/2002	
	F		WO 2004/111189		Merck & Co., Inc.	12/23/2004	
	G		WO 2003/072041		Merck & Co., Inc.	09/04/2003	
			7.4,				

Examiner Signature

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449B/PTO				COMPLETE IF KNOWN		
_	INFORMATION DISCLOSURE			Application Number	To Be Assigned 2 9 9 CFD 2005	
e.	TATENTENIT DS/	7 A YO		Filing Date	September 28, 10/59483 E	
3	STATEMENT BY APPLICANT			First Named Inventor	Craig A. Coburn et al.	
			,	Group Art Unit	To Be Assigned	
	(use as many sheets as necessary)			Examiner Name	To Be Assigned	
Sheet	2	of	2	Attorney Docket Number	21538YP	

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	Н	M. Ono et al., "Benzofuran derivatives as Alpha Beta-aggregate-specific imaging agents for Alzheimer's Disease," Nuclear Medicine and Biology, Vol. 29, pp. 633-642 (2002)
	I	D. Allsop et al., "3-p-Toluoyl-2-[4'-(3-diethylaminopropoxy)-phenyl]-benzofuran and," Bioorganic & Medicinal Chemistry Letters, Vol. 11, pp. 255-257 (2001)
	J	D. Howlett et al., "Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans," Biochem. J, Vol. 340, pp. 283-289 (1999)
	K	Xiao-Ping Shi et al., "Beta-Secretase Cleavage at Amino Acid Residue 34 in the Amyloid Beta Peptide Is Dependent upon Gamma-Secretase Activity," J. Biological Chemistry, Vol. 278, No. 23, pp. 21286-21294 (2003)
	L	N. Ida et al., "Analysis of Heterogeneous Beta Alpha 4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay," J. Biological Chemistry, Vol. 271, No. 37, pp. 22908-22914 (1996)
	М	Y. Li et al., "Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state," PNAS, Vol. 97, No. 11, pp. 6138-6143 (2000)

Examiner Signature	Date Considered	

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.